Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.
You may also be interested in...
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.